Daiichi Sankyo Access Central offers financial assistance for eligible patients prescribed Injectafer. Call 1-866-4-DSI-NOW to learn how to help your patients access Injectafer.
Has commercial insurance
Is a resident of the USA or its territories, including Puerto Rico
Has Medicare, Medicaid, or other federal or state healthcare insurance
Has private indemnity or HMO insurance that reimburses patients for the entire cost of prescription drugs
Is Medicare-eligible and enrolled in an employer-sponsored health plan or medical or prescription drug benefit program for retirees
* The Injectafer Savings Program is only available for patients aged 1 year or older who are commercially insured. Please see full Terms and Conditions.
† When forms are uploaded to injectafercopay.com, the process may potentially be expedited. For patients who wish to directly submit their EOB form, please direct them to fax or mail the form to the Injectafer Savings Program.
Injectafer Savings Program Terms and Conditions
Q: What is the Injectafer Savings Program?
A: The Injectafer Savings Program helps patients being treated with Injectafer with their prescription out-of-pocket responsibility.
Q: Is the Injectafer Savings Program only valid on Injectafer prescriptions?
A: Yes, the program can only be used toward a patient's prescription out-of-pocket responsibility for the Injectafer medication.
Q: How much can a patient save?
A: The program helps with up to $500 per dose. A patient can save a maximum benefit of up to $1000 per course of treatment. Enrollment is valid for 2 courses of treatment per 12-month period.
Q: Which patients are eligible to participate?
A: Commercially insured patients are eligible to enroll. Cash-paying patients and patients with drug coverage under any federally funded healthcare program, including but not limited to Medicare, Medicaid, TRICARE, or other state-funded programs (collectively FHCP), will be ineligible to participate.
Q: If I recommend additional therapy with Injectafer, can my patient still use the program?
A: Yes, if you recommend additional treatment with Injectafer, the program will help cover your patient’s prescription out-of-pocket responsibility. The offer is valid for 2 courses of an Injectafer prescription. An explanation of benefits statement must be faxed, uploaded in the portal, or mailed in prior to transacting on the account numbers for assistance. One enrollment is allowed per 12-month period.
Q: How does the Injectafer Savings Program work?
A: An interested patient can visit the Savings Program website and enroll in the program or you can enroll the patient on their behalf. Following confirmation of eligibility, an Injectafer Savings Program virtual debit card number will be issued to the patient; that number is then given to the patient's healthcare provider. The Savings Program requires that once the patient receives each dose, an explanation of benefits or itemized statement from his or her healthcare provider be sent to the program via fax, mail, or the upload tool. The program fax number is 1-888-257-4673. Once this information is received, the claims department will load funds to the virtual card within 2-3 business days.
Q: Is proof of purchase necessary?
A: Yes. After each dose, you and your patient will receive an explanation of benefits form from your patient's insurance provider. This document will need to be sent to the program to load funds to the patient's virtual debit card. There are 3 ways to send the EOB form: 1. Upload at injectafercopay.com (this is the best way to submit EOBs and manage all patients); 2. Fax to 1-888-257-4673; 3. Mail to Injectafer Savings Program, 100 Passaic Ave, Suite 245, Fairfield, NJ 07004.
Q: What happens if an explanation of benefits is not sent in?
A: The funds will not be available to the patient until this documentation is submitted.
Q: What do I do if my practice cannot process credit or debit cards?
A: In situations where a dispensing entity does not accept debit or credit card payments, the program will provide reimbursement for the patient's eligible out-of-pocket expense in accordance with the program via paper check upon receiving a receipt of the incurred out-of-pocket expense for Injectafer. To do this, you will need a check request form. (The best place to get the form is online at injectafercopay.com or, alternately, by calling 1-866-4-DSI-NOW.) If your office requires a 3-digit security code for processing, please call us at 1-877-448-4766.
Q: What if I administer Injectafer before my patient has enrolled in the Savings Program?
A: Qualified patients receiving Injectafer will be allowed a 120-day retroactive enrollment period to receive benefits under the program rules.
The completion and submission of coverage- or reimbursement-related documentation is the responsibility of the patient and healthcare provider. Daiichi Sankyo, Inc., makes no representation or guarantee concerning coverage or reimbursement for any service or item. A completed form includes signatures from both the physician and the patient. Before submitting, please ensure all required information is provided.
Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.
Symptomatic hypophosphatemia with serious outcomes including osteomalacia and fractures requiring clinical intervention has been reported in patients treated with Injectafer in the post-marketing setting. These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment. However, symptomatic hypophosphatemia has been reported after one dose. Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, inflammatory bowel disease, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, and malnutrition. In most cases, hypophosphatemia resolved within three months.
Correct pre-existing hypophosphatemia prior to initiating therapy with Injectafer. Monitor serum phosphate levels in patients at risk for chronic low serum phosphate. Check serum phosphate levels prior to a repeat course of treatment in patients at risk for low serum phosphate and in any patient who receives a second course of therapy within three months. Treat hypophosphatemia as medically indicated.
Hypersensitivity ReactionsSerious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.
HypertensionIn clinical studies, hypertension was reported in 4% (67/1775) of subjects in clinical trials 1 and 2. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects in these two clinical trials. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.
Laboratory Test AlterationsIn the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.
In two randomized clinical studies [Studies 1 and 2], a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a maximum single dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by >2% of Injectafer-treated patients were nausea (7.2%); hypertension (4%); flushing (4%); injection site reactions (3%); erythema (3%); hypophosphatemia (2.1%); and dizziness (2.1%).
PediatricThe safety of Injectafer in pediatric patients was evaluated in Study 3. Study 3 was a randomized, active-controlled study in which 40 patients (1 to 12 years of age: 10 patients, 12 to 17 years of age: 30 patients) received Injectafer 15 mg/kg to a maximum single dose of 750 mg (whichever was smaller) on Days 0 and 7 for a maximum total dose of 1500 mg; 38 patients evaluable for safety in the control arm received an age-dependent formulation of oral ferrous sulfate for 28 days. The median age of patients who received Injectafer was 14.5 years (range, 1-17); 83% were female; 88% White and 13% Black. The most common adverse reactions (≥4%) were hypophosphatemia (13%), injection site reactions (8%), rash (8%), headache (5%), and vomiting (5%).
Patients with Iron Deficiency and Heart FailureThe safety of Injectafer was evaluated in adult patients with iron deficiency and heart failure in randomized controlled trials FAIR-HF (NCT00520780), CONFIRM-HF (NCT01453608) and AFFIRM-AHF (NCT02937454) in which 1016 patients received Injectafer versus 857 received placebo. The overall safety profile of Injectafer was consistent across the studied indications.
Post-Marketing ExperienceThe following adverse reactions have been identified during post approval use of Injectafer. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported from the post-marketing spontaneous reports with Injectafer: cardiac disorders: tachycardia; general disorders and administration site conditions: chest discomfort, chills, pyrexia; metabolism and nutrition disorders: hypophosphatemia; musculoskeletal and connective tissue disorders: arthralgia, back pain, hypophosphatemic osteomalacia; nervous system disorders: syncope; respiratory, thoracic and mediastinal disorders: dyspnea; skin and subcutaneous tissue disorders: angioedema, erythema, pruritus, urticaria; pregnancy: fetal bradycardia.
Untreated IDA in pregnancy is associated with adverse maternal outcomes such as postpartum anemia. Adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight.
Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with parenteral iron products (such as Injectafer) which may cause fetal bradycardia, especially during the second and third trimester.
You are encouraged to report Adverse Drug Events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Injectafer ® (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron, and in adult patients who have non-dialysis dependent chronic kidney disease. Injectafer is also indicated for iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity.
Please click here for Important Safety Information and full Prescribing Information for Injectafer.American Regent, Inc. is a member of the Daiichi Sankyo Group.
Injectafer ® and the Injectafer ® logo are trademarks of Vifor (International) Inc., Switzerland.
Injectafer ® is manufactured under license from Vifor (International) Inc., Switzerland.
Trademarks not owned by American Regent, Inc. or Vifor (International) are the property of their respective owners.
Access Central ™ is a trademark of Daiichi Sankyo, Inc.
©2024 Daiichi Sankyo, Inc. All Rights Reserved.
American Regent, Inc. is a member of the Daiichi Sankyo Group.
Injectafer ® and the Injectafer ® logo are trademarks of Vifor (International) Inc., Switzerland.
Injectafer ® is manufactured under license from Vifor (International) Inc., Switzerland.
Trademarks not owned by American Regent, Inc. or Vifor (International) are the property of their respective owners.
Access Central ™ is a trademark of Daiichi Sankyo, Inc.
©2024 Daiichi Sankyo, Inc. All Rights Reserved.
This site is intended only for U.S. healthcare professionals and/or healthcare professionals involved in healthcare reimbursement.
Please note:
You are now being directed to an external site that is not owned or monitored by Daiichi Sankyo, Inc.
Please note:
You are now being directed to another Daiichi Sankyo website.
Please note:
Please be advised that you are now leaving Access Central.
